First patients Enrolled in Immuron’s IMM-529 Clinical Study at Hadassah Medical Center in Israel
January 31, 2018 – Immuron (ASX:IMC) (NASDQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immune-therapeutics for the treatment of gut mediated diseases,
Shaare Zedek Medical Center Signs MoU with Indian Central Council for Research in Homeopathy
January 18, 2018 The Centre for Integrative Complementary Medicine of Shaare Zedek Medical Center in Jerusalem signed a pact with the Central Council for Research in Homoeopathy, Ministry of AYUSH. The pact is
Intec Pharma Names R. Michael Gendreau, M.D., Ph.D. as CMO
January 31, 2018 – Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC), a clinical stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion Pill™ platform
The MUSE(TM) Procedure for GERD Treatment Performed First Time in Israel at Shaare-Zedek Medical Center
Dec 27, 2017 – Dr. Wengrower, Head, Therapeutic Endoscopy Unit, and his colleagues Dr. Paz and Dr. Livovsky at the Digestive Diseases Institute, Shaare-Zedek Medical
First Annual OurCrowd Maimonides Award for Lifetime Achievement in Science, Leadership and Menschlichkeit, was given this year to Dr. Morry Blumenfeld
Feb 1, 2018 Dr. Morry Blumenfeld, a legend in the field of medical technology development as well as MedTech investment, was given the First Annual
The 2018 OurCrowd Global Investment Summit highlighted Israeli Digital Health Technologies
Feb 5, 2018 OurCrowd, one of the largest investment crowdfunding platforms in the world, held their annual summit at the International Convention Center in Jerusalem February 1.
Opportunities for Israeli Companies in Mexico and California
Here are the Highlights of the Cali-Israel-Mexico Innovation Expo Recruitment Presentation January 24th, 2018, Jerusalem Israel. JLM-BioCity, JBNF, Regus Co-Working Space, and the Cali-Israel-Mexico Innovation
JLM based Entera Bio sets terms for $60m Nasdaq IPO
DNA Biomedical Solutions Ltd. (TASE: DNA) subsidiary Entera Bio has set the terms for a Nasdaq IPO to raise $50 million – $60 million at a company valuation
Oramed Pharma’s CEO Issues Letter to Shareholders
Jan 19, 2017 Dear Shareholders, All the hard work and dedication in 2017 has successfully positioned Oramed to initiate a U.S. based multicenter 90-day treatment
